Rentschler Biopharma awarded Chiesi Supplier Award

• Chiesi Group recently presented Rentschler Biopharma with the We Excel in Innovation and Collaboration Award
• During Chiesi’s Vendor Day, Supplier Awards presented to companies that have achieved outstanding results in the area of sustainability

Laupheim, Germany, December 19, 2022 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that its long-standing client, Chiesi Group, recently presented Rentschler Biopharma with the We Excel in Innovation and Collaboration Award. During Chiesi Group’s Vendor Day, an event that brings together Chiesi’s main suppliers to discuss best practices in terms of quality, service, innovation, and collaboration, the Supplier Awards 2022 were presented to partners recognized as outstanding in four categories.

Rentschler Biopharma won the We Excel in Innovation and Collaboration Award, given to companies with outstanding records in these areas based on an internal assessment survey. In terms of innovation, Chiesi assessed the technologies, processes, ideas, and methods that companies have developed to the benefit of the Chiesi Group. The level of collaboration assessed reflects the supplier's proactivity in anticipating and solving problems and the consistency between its promises and Chiesi’s expectations.

Rino Visentin, Manager External Manufacturing at Chiesi Group, who presented the award, commented: “It is a great pleasure for Chiesi to reward the excellence of Rentschler Biopharma as a true example of a partnership that has been going on for more than seven years. An example of attention to rare diseases, to the patients who suffer from them and the construction of sustainable values for the entire community.”

“It is truly an honor for us to be recognized by our long-term client, Chiesi, for our innovation and collaboration – two values that are core to our business and areas where we strive to be industry leaders. Our focus is on building sustainable value for our clients and for patients, and it is the dedication, hard work and forward thinking of our employees that enable Rentschler Biopharma to excel. I celebrate the entire team,” commented Federico Pollano, Senior Vice President Business Development of Rentschler Biopharma, who accepted the award on behalf of the company during the meeting in Parma, Italy.

Rentschler Biopharma has been working with Chiesi (previously Zymenex, which was acquired by Chiesi) to manufacture the biological active substance for Lamzede^®, a recombinant enzyme since 2009. Rentschler Biopharma manufactured study material for Phase I through to approval and has produced commercial supply since 2018, when Lamzede^® was approved in the EU and UK to treat mild to moderate alpha-mannosidosis, a rare inherited metabolic disorder. Lamzede® is one of several products marketed by Chiesi, a company working with partners like Pfizer or Merck, operating in 30 countries and with more than 6,000 employees.

Alpha-mannosidosis
Alpha-mannosidosis is an ultra-rare genetic disorder characterized by a deficiency of the enzyme alpha mannosidase. This enzyme deficiency results in the body’s cells being unable to properly break down certain groups of complex sugars. The buildup of sugars can affect many parts of the body’s organs and systems, like the central nervous system. Effects of the disease vary significantly, and symptoms can include recurrent chest and ear infections, hearing loss, distinctive facial features, muscle weakness, skeletal and joint abnormalities, or cognitive abnormalities. Alpha-mannosidosis affects approximately 1 in 1,000,000 babies born worldwide.

Chiesi Group Vendor Day
Vendor Day was inaugurated in 2019 by Chiesi Group and all its suppliers. The event showcases the strategic projects implemented by Chiesi and the medium- to long-term objectives that the Group plans to achieve with the help of its partners, particularly in the field of sustainability. The Supplier Awards are granted to those companies that have achieved outstanding results in the area of sustainability. There are four categories of awards granted to companies that have stood out in the key areas: “Best Supplier for People and Planet”, “We Excel in Innovation and Collaboration”, “We Excel in Sustainability”, “We Excel in Quality and Service Level”.

Chiesi Group
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. 

By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. Since 2019 Chiesi is certified B Corp, meaning that its sustainability efforts are measured and assessed by the most ambitious global standards. The company aims at becoming net-zero by 2035.

With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 30 countries, and counts more than 6,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit

About Rentschler Biopharma SE
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

For further information, please visit . Follow Rentschler Biopharma on and .

Contact:
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication
Phone: 4

Media inquiries:

For a high-resolution image, please contact .